Sarcoma Synovial clinical trials

Explore recruiting sarcoma synovial clinical trials.

Recruiting sarcoma synovial studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Sarcoma Synovial trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas

Spain

Phase I and Phase II (Integrated)- Bioequivalence Study EU CTIS Study details

Sarcoma Synovial trials by city

Sarcoma Synovial in Toronto Sarcoma Synovial in Vancouver Sarcoma Synovial in Montreal Sarcoma Synovial in Calgary Sarcoma Synovial in Edmonton Sarcoma Synovial in Ottawa Sarcoma Synovial in Winnipeg Sarcoma Synovial in Quebec City Sarcoma Synovial in Hamilton Sarcoma Synovial in Kitchener Sarcoma Synovial in London Sarcoma Synovial in Halifax Sarcoma Synovial in New York Sarcoma Synovial in Los Angeles Sarcoma Synovial in Chicago Sarcoma Synovial in Houston

Sarcoma Synovial clinical trials

Recruiting sarcoma synovial studies right now

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

AOH1996 for the Treatment of Refractory Solid Tumors

Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies

XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma

ACTengine® IMA203 Combined With mRNA-4203

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas

Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma

Also recruiting in Europe

Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas

Sarcoma Synovial trials by city

Other conditions